PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Persistence of Anti-SARS-CoV-2 Antibodies Six Months After Infection in an Outbreak With Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study
Version 1
: Received: 20 May 2021 / Approved: 21 May 2021 / Online: 21 May 2021 (15:41:51 CEST)
Version 2
: Received: 22 September 2021 / Approved: 23 September 2021 / Online: 23 September 2021 (11:10:54 CEST)
Domènech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Vidal-Utrillas, P.; Latorre-Poveda, M.; Del Rio-González, A.; Ferrando-Rubert, S.; Ferrer-Abad, G.; Sánchez-Urbano, M.; Aparisi-Esteve, L.; Badenes-Marques, G.; Cervera-Ferrer, B.; Clerig-Arnau, U.; Dols-Bernad, C.; Fontal-Carcel, M.; Gomez-Lanas, L.; Jovani-Sales, D.; León-Domingo, M.C.; Llopico-Vilanova, M.D.; Moros-Blasco, M.; Notari-Rodríguez, C.; Ruíz-Puig, R.; Valls-López, S.; Arnedo-Pena, A. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. COVID2021, 1, 71-82.
Domènech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Vidal-Utrillas, P.; Latorre-Poveda, M.; Del Rio-González, A.; Ferrando-Rubert, S.; Ferrer-Abad, G.; Sánchez-Urbano, M.; Aparisi-Esteve, L.; Badenes-Marques, G.; Cervera-Ferrer, B.; Clerig-Arnau, U.; Dols-Bernad, C.; Fontal-Carcel, M.; Gomez-Lanas, L.; Jovani-Sales, D.; León-Domingo, M.C.; Llopico-Vilanova, M.D.; Moros-Blasco, M.; Notari-Rodríguez, C.; Ruíz-Puig, R.; Valls-López, S.; Arnedo-Pena, A. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. COVID 2021, 1, 71-82.
Domènech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Vidal-Utrillas, P.; Latorre-Poveda, M.; Del Rio-González, A.; Ferrando-Rubert, S.; Ferrer-Abad, G.; Sánchez-Urbano, M.; Aparisi-Esteve, L.; Badenes-Marques, G.; Cervera-Ferrer, B.; Clerig-Arnau, U.; Dols-Bernad, C.; Fontal-Carcel, M.; Gomez-Lanas, L.; Jovani-Sales, D.; León-Domingo, M.C.; Llopico-Vilanova, M.D.; Moros-Blasco, M.; Notari-Rodríguez, C.; Ruíz-Puig, R.; Valls-López, S.; Arnedo-Pena, A. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. COVID2021, 1, 71-82.
Domènech-Montoliu, S.; Puig-Barberà, J.; Pac-Sa, M.R.; Vidal-Utrillas, P.; Latorre-Poveda, M.; Del Rio-González, A.; Ferrando-Rubert, S.; Ferrer-Abad, G.; Sánchez-Urbano, M.; Aparisi-Esteve, L.; Badenes-Marques, G.; Cervera-Ferrer, B.; Clerig-Arnau, U.; Dols-Bernad, C.; Fontal-Carcel, M.; Gomez-Lanas, L.; Jovani-Sales, D.; León-Domingo, M.C.; Llopico-Vilanova, M.D.; Moros-Blasco, M.; Notari-Rodríguez, C.; Ruíz-Puig, R.; Valls-López, S.; Arnedo-Pena, A. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study. COVID 2021, 1, 71-82.
Abstract
In March 2020, several mass gathering events were related to the Falles festival in Borriana (Spain), resulting in a 536 laboratory-confirmed COVID-19 cases outbreak among participants. Our objective was to estimate anti-SARS-CoV-2 antibodies persistence six months after and factors associated with antibody response. A prospective population-based cohort study was carried out by the Public Health Center of Castellon and the Emergency and Clinical Analysis and Microbiology Services of Hospital de la Plana in Vila-real. In October 2020, sero-epidemiologic study to estimate the persistence of anti-SARS-CoV-2 antibodies by a electrochemiluminescence immunoassay (ECLIA) was implemented. We enrolled 484 (90.2%) of the 536 members of the initial outbreak cohort and detected persistent antibodies in 479 (99%) without re-infection episodes. Five participants had a negative antibody test. Factors associated with a negative result were a lower body mass index (BMI), and less contact with other COVID-19 cases. Among the 469 participants with two ECLIA tests, 96 (20.5%) had an increase of antibodies and 373 (79.5%) a decline. Increased antibodies were associated with older age, higher BMI, more severe illness, and low current smokers. After a COVID-19 infection, a high proportion of cases maintained detectable anti-SARS-CoV-2 antibodies.
Keywords
SARS-CoV-2; COVID-19; antibodies; cohort; population-based; body mass index; ECLIA
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.